T. Rowe Price Associates
ADPT icon

T. Rowe Price Associates’s Adaptive Biotechnologies ADPT Stock Holding History

T. Rowe Price Associates’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.2M Buy
2,665,308
+1,099,095
+70% +$16.8M 0.01% 850
2026
Q1 		$21.7M Sell
1,566,213
-2,821,148
-64% -$44.9M ﹤0.01% 1015
2025
Q4 		$71.3M Buy
4,387,361
+3,299,635
+303% +$53.9M 0.01% 709
2025
Q3 		$16.3M Buy
1,087,726
+965,524
+790% +$11.8M ﹤0.01% 1101
2025
Q2 		$1.42M Buy
122,202
+22,740
+23% +$207K ﹤0.01% 1809
2025
Q1 		$740K Buy
99,462
+5,570
+6% +$42.8K ﹤0.01% 2095
2024
Q4 		$563K Sell
93,892
-65,931
-41% -$364K ﹤0.01% 2241
2024
Q3 		$819K Buy
159,823
+1,016
+0.6% +$4.43K ﹤0.01% 2048
2024
Q2 		$575K Buy
158,807
+3,578
+2% +$11.4K ﹤0.01% 2135
2024
Q1 		$499K Sell
155,229
-137,655
-47% -$533K ﹤0.01% 2212
2023
Q4 		$1.44M Sell
292,884
-15,867
-5% -$72.4K ﹤0.01% 1697
2023
Q3 		$1.68M Sell
308,751
-1,238,541
-80% -$8.19M ﹤0.01% 1540
2023
Q2 		$10.4M Sell
1,547,292
-211,657
-12% -$1.57M ﹤0.01% 1077
2023
Q1 		$15.5M Sell
1,758,949
-79,517
-4% -$701K ﹤0.01% 977
2022
Q4 		$14M Sell
1,838,466
-53,618
-3% -$417K ﹤0.01% 993
2022
Q3 		$13.5M Sell
1,892,084
-10,291,811
-84% -$96.9M ﹤0.01% 1011
2022
Q2 		$98.6M Sell
12,183,895
-232,472
-2% -$2.04M 0.01% 670
2022
Q1 		$172M Sell
12,416,367
-870,346
-7% -$13.7M 0.02% 571
2021
Q4 		$373M Buy
13,286,713
+1,840,491
+16% +$56.4M 0.03% 405
2021
Q3 		$389M Buy
11,446,222
+479,331
+4% +$17.3M 0.04% 392
2021
Q2 		$448M Buy
10,966,891
+1,342,666
+14% +$52.2M 0.04% 361
2021
Q1 		$387M Buy
9,624,225
+3,669,449
+62% +$199M 0.04% 383
2020
Q4 		$352M Buy
5,954,776
+2,114,378
+55% +$109M 0.04% 399
2020
Q3 		$187M Buy
3,840,398
+1,117,025
+41% +$46.9M 0.02% 500
2020
Q2 		$132M Sell
2,723,373
-580,147
-18% -$21.2M 0.02% 565
2020
Q1 		$91.8M Buy
3,303,520
+1,101,522
+50% +$30.7M 0.01% 595
2019
Q4 		$65.9M Buy
2,201,998
+1,495,074
+211% +$42.9M 0.01% 805
2019
Q3 		$21.8M Sell
706,924
-193,076
-21% -$7.88M ﹤0.01% 1118
2019
Q2 		$43.5M Buy
+900,000
New +$39.9M 0.01% 935

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

T. Rowe Price Associates's ADPT Position: Q2 2026 in Review

T. Rowe Price Associates increased its Adaptive Biotechnologies (ADPT) stake by 70% in Q2 2026, buying an estimated $16.8M and bringing the position to 2,665,308 shares worth $57.2M. The position accounts for 0.01% of the portfolio, ranked #850.

T. Rowe Price Associates first reported a position in ADPT in Q2 2019 and has held it in 29 quarters since. The position peaked at $448M in Q2 2021. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • T. Rowe Price Associates held 2,665,308 shares of Adaptive Biotechnologies worth $57.2M as of Q2 2026.
  • T. Rowe Price Associates bought 1,099,095 Adaptive Biotechnologies shares in Q2 2026, an estimated $16.8M.
  • Adaptive Biotechnologies made up 0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #850 holding.
  • T. Rowe Price Associates first reported a position in Adaptive Biotechnologies in Q2 2019 and has held it in 29 quarters since.
  • T. Rowe Price Associates's Adaptive Biotechnologies position peaked at $448M in Q2 2021.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.